This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Dexcel Pharma Technologies Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Nadav Marbach-Bar: Innovator in Nucleic Acid Technology
Introduction
Nadav Marbach-Bar is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acids for medical applications. His work focuses on innovative solutions for treating diseases associated with transferrin receptor 2.
Latest Patents
Nadav holds 1 patent for his invention titled "Nucleic acids for inhibiting expression of transferrin receptor 2." This patent provides nucleic acids and compositions designed to inhibit the expression of transferrin receptor 2 (TFR2). The invention also outlines methods for treating TFR2-associated diseases, such as anemia, using the disclosed nucleic acids.
Career Highlights
Nadav is currently associated with Dexcel Pharma Technologies Ltd., where he continues to advance his research and development efforts. His work at Dexcel Pharma has positioned him as a key player in the biotechnology sector, contributing to innovative therapeutic solutions.
Collaborations
Nadav collaborates with talented professionals in his field, including Elena Feinstein and Noa Madar-Balakirski. These collaborations enhance the research and development process, fostering innovation and progress in their projects.
Conclusion
Nadav Marbach-Bar is a dedicated inventor whose work in nucleic acid technology holds promise for treating significant medical conditions. His contributions to the field exemplify the impact of innovative research on healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile